Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor
Phase of Trial: Phase I/II
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Anti-MUC1 CAR-T cell therapy (Primary)
- Indications Colorectal cancer; Gastric cancer; Glioma; Oesophageal cancer
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 11 Jul 2016 Status changed from suspended to recruiting.
- 21 Jun 2016 Status changed from recruiting to suspended.
- 03 Dec 2015 New trial record